Patents Represented by Attorney, Agent or Law Firm Charlene A. Launer
  • Patent number: 6825333
    Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: November 30, 2004
    Assignee: Chiron Corporation
    Inventors: W. Michael Kavanaugh, Hui Cen, Pauline Lee
  • Patent number: 6809194
    Abstract: Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and for regulating cell growth, particularly tumor cell growth, are also provided.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: October 26, 2004
    Assignee: Chiron Corporation
    Inventors: Christoph Reinhard, Anne B. Jefferson
  • Patent number: 6743602
    Abstract: The present invention features human HX2004-6 polypeptide and nucleotide sequences encoding HX2004-6 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human HX2004-6 polypeptide. The present invention also relates to antibodies that bind specifically to a human HX2004-6 polypeptide. Further provided are diagnostic and screening methods using HX2004-6 polynucleotides and antibodies specific for HX2004-6 polypeptides.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: June 1, 2004
    Assignee: Chiron Corporation
    Inventor: Giulia C. Kennedy
  • Patent number: 6703221
    Abstract: The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: March 9, 2004
    Assignee: Chiron Corporation
    Inventors: Vivien Chan, Michael Rohan, Lewis T. Williams
  • Patent number: 6673911
    Abstract: A human oncogene and its expression products can be used as diagnostic, prognostic, and therapeutic tools for neoplastic disorders. Nucleotide sequences of the gene can also be used to identify a p34.3 region of a human chromosome 1.
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: January 6, 2004
    Assignee: Chiron Corporation
    Inventor: Filippo M. Randazzo
  • Patent number: 6613956
    Abstract: Polynucleotide constructs encoding growth factor independent catalytically active membrane targeted PI 3-kinase mutants useful for therapeutic and research purposes are described. In addition, a method for using the polynucleotide constructs to screen for inhibitors of PI 3-kinase, a method for making 3′ phosphorylated inositol phospholipids, methods of reducing cell death after trauma, and methods of overcoming insulin resistance are described.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: September 2, 2003
    Assignee: Chiron Corporation
    Inventors: Anke Klippel, W. Michael Kavanaugh, Stephen D. Harrison, Lewis T. Williams
  • Patent number: 6579521
    Abstract: Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 17, 2003
    Assignee: Chiron Corporation
    Inventor: David Sahner
  • Patent number: 6525102
    Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: February 25, 2003
    Assignee: Chiron Corporation
    Inventors: Bao-Lu Chen, Maninder S. Hora
  • Patent number: 6242414
    Abstract: Methods of treatment and prevention of diseases associated with release of neutrophil elastase and IL-8 by administration of TFPI, and analogs of TFPI are disclosed. Methods of determining efficacy of treatment with TFPI, patient's responsiveness to treatment with TFPI and the ultimate determination of patient prognosis are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 5, 2001
    Assignees: Chiron Corporation, Central Laboratory of The Netherlands Red Cross Blood Tranfusion Service
    Inventors: Kirk Johnson, Abla A. Creasey, Lucien A. Aarden
  • Patent number: 5615526
    Abstract: An inexpensive drain assembly for draining water from flat roofs, balconies, decks and other flat or low sloping surfaces that are covered with a water-tight single layer synthetic roofing and waterproofing membrane. The drain assembly includes a grate having a strainer and a connecting collar, a flanged boot that is contoured to fit snugly around the collar of the grate and is sealed via the flange to the synthetic membrane, and a pipe connector that connects the grate and contoured boot to a standard drain pipe. The flanged boot is made from elastomer that is identical to or compatible with and sealably attachable to the synthetic membrane. The elastomer and the synthetic membrane are made of materials selected from a group consisting of synthetic rubber, rubber-like materials, plastic, and plastic-like materials.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: April 1, 1997
    Inventors: Dale W. Palmer, John F. Pittman
  • Patent number: 5616477
    Abstract: Novel fusion proteins that enhance the immune response of an antigen are efficiently expressed and secreted by yeast host cells. The fusion proteins are recombinantly made by fusing the 3'-end of mature GM-CSF DNA sequence to the 5'-end of an antigen DNA sequence with or without a linker sequence. Methods of expression in yeast cells are provided.
    Type: Grant
    Filed: May 2, 1996
    Date of Patent: April 1, 1997
    Assignee: Immunex Corporation
    Inventor: Virginia L. Price
  • Patent number: 5266311
    Abstract: Cloning and expression of DNA segments encoding bovine IL-1.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: December 23, 1991
    Date of Patent: November 30, 1993
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Charles R. Maliszewski, Michael Schoenborn